DSS, Inc.

What they do

The Product Packaging segment is led by wholly owned subsidiary Premier Packaging Corporation, which makes folding cartons, mailers, photo sleeves and 3-D direct mail from a facility in Rochester, NY, mainly for the US market. Biotechnology is organized under DSS BioHealth Security, Inc. and pursues research in a universal therapeutic drug platform, a sugar substitute, and a multi-use fragrance, with operations in Houston, TX and Rochester, NY. Commercial Lending is conducted through American Pacific Financial, Inc., offering business lines of credit, land development, inventory and equipment financing and third-party loan servicing. Securities and Investment Management includes DSS Securities, Inc. and affiliates, and a real estate investment trust that acquires hospitals and care centers.

Revenue drivers

• Printed products (Product Packaging) — Fiscal 2025 printed products revenue was $18.085 million, up 12% from $16.107 million in 2024, and it is by far the largest revenue line, driven by new customer orders and existing orders exceeding forecasts.
• Commission (Securities and Investment Management) — Commission revenue was $1.353 million in fiscal 2025, up 39% from $972,000 in 2024, and the segment includes broker-dealer and advisory activity.
• Rental — Rental income was $1.236 million in fiscal 2025, down 31% from $1.792 million in 2024, tied to real estate investment entities associated with the securities/investment management division.
• Commercial Lending — Commercial lending revenue was $45,000 in fiscal 2025, down 80% from $226,000 in 2024; management says it intends to shift away from direct marketing toward inventory/equipment loans and broker/dealer loans.

Recent performance

For the six months ended June 30, 2026, Product Packaging revenue was $7.438 million, down 10% from $8.286 million in the prior-year period, with the second quarter alone down 24% to $3.258 million. Securities revenue fell 75% to $475,000 for the six months, Commercial Lending fell 63% to $11,000, and Biotechnology revenue was $10,000. Total quarterly revenue in the XBRL data declined across the trailing four quarters from $6.4 million (2025-09-30) to $3.6 million (2026-06-30). Full-year 2025 revenue was $20.757 million, up 9% from $19.097 million in 2024, and full-year 2025 net loss narrowed to $23.9 million from $46.9 million in 2024. At June 30, 2026, total assets were $68.4 million, total liabilities were $59.9 million, and shareholder equity was negative $382,000.

Strategy

Management's stated 2025 priorities were operational efficiency, portfolio optimization, capital discipline and long-term value creation. In April 2025, the company sold the Celios air purification asset to Impact BioMedical in an all-equity transaction valued at approximately $1.15 million as part of portfolio streamlining. In April 2025, Sentinel Brokers Company, a FINRA-registered broker-dealer subsidiary, received FINRA approval to act as an underwriter and selling group member for corporate securities offerings. The commercial lending division is being repositioned away from direct marketing toward inventory/equipment loans and broker-dealer loans. DSS says it reports only the four current segments and may add other divisions once they generate material revenue.

Risks

• Impairment of intangibles — As of December 31, 2025, DSS had approximately $17.0 million of net intangible assets, essentially all associated with Impact BioMedical, Inc., and the company states these values could be reduced if licensing efforts are not successful.
• Negative shareholder equity — Shareholder equity was negative $382,000 at June 30, 2026, against total liabilities of $59.9 million, leaving limited book cushion.
• Secured indebtedness obligations — The 10-K risk factors state the company has secured indebtedness and faces a potential risk that it may be unable to satisfy interest and principal obligations when due.
• Concentrated and declining revenue — Product Packaging supplied $18.1 million of $20.8 million in fiscal 2025 revenue, and packaging revenue fell 10% in the first half of 2026 while securities, lending and biotech revenue were each under $0.5 million for the six months.

Outlook

Management describes the four business lines as being at various stages of development, growth and income generation, and says additional operating segments may be added to reporting as they become material. For commercial lending, the stated direction is to grow the inventory/equipment loan portfolio and expand into specialized lending such as broker/dealer loans while monitoring the managed loan portfolio. The 10-K recap cites ongoing portfolio optimization and capital discipline, and notes that the equity portfolio held as a bank holding company is expected to remain relatively stable regardless of stock market fluctuations.